Abstract
Somatic cells show a spontaneous decline in growth rate in continuous culture. This is not related to elapsed time but to an increasing number of population doublings, eventually terminating in a quiescent but viable state, termed replicative senescence. These cells are commonly multinucleated and do not respond to mitogens or apoptotic stimuli. Cells displaying characteristics of senescent cells can also be observed in response to other stimuli, such as oncogenic stress, DNA damage or cytotoxic drugs, and have been reported to be found in vivo. Most tumors show unlimited replicative potential, leading to the hypothesis that cellular senescence is a natural antitumor program. Recent findings suggest that cellular senescence is a natural mechanism to prevent undesired oncogenic stress in somatic cells that has been lost in malignant tumors. Given that the ultimate goal of cancer research is to find the definitive cure for as many tumor types as possible, exploration of cellular senescence to drive towards antitumor therapies may decisively influence the outcome of new drugs. In the present work we will review the potential of cellular senescence to be used as target for anticancer therapy.
Keywords: Cellular senescence, immortality, telomere shortening, senescence targets
Current Cancer Therapy Reviews
Title: Cellular Senescence as a Target in Cancer Control
Volume: 3 Issue: 1
Author(s): Amancio Carnero
Affiliation:
Keywords: Cellular senescence, immortality, telomere shortening, senescence targets
Abstract: Somatic cells show a spontaneous decline in growth rate in continuous culture. This is not related to elapsed time but to an increasing number of population doublings, eventually terminating in a quiescent but viable state, termed replicative senescence. These cells are commonly multinucleated and do not respond to mitogens or apoptotic stimuli. Cells displaying characteristics of senescent cells can also be observed in response to other stimuli, such as oncogenic stress, DNA damage or cytotoxic drugs, and have been reported to be found in vivo. Most tumors show unlimited replicative potential, leading to the hypothesis that cellular senescence is a natural antitumor program. Recent findings suggest that cellular senescence is a natural mechanism to prevent undesired oncogenic stress in somatic cells that has been lost in malignant tumors. Given that the ultimate goal of cancer research is to find the definitive cure for as many tumor types as possible, exploration of cellular senescence to drive towards antitumor therapies may decisively influence the outcome of new drugs. In the present work we will review the potential of cellular senescence to be used as target for anticancer therapy.
Export Options
About this article
Cite this article as:
Carnero Amancio, Cellular Senescence as a Target in Cancer Control, Current Cancer Therapy Reviews 2007; 3 (1) . https://dx.doi.org/10.2174/157339407780126629
DOI https://dx.doi.org/10.2174/157339407780126629 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature
Current Drug Targets HLA Class I Expression, Tumor Escape and Cancer Progression
Current Cancer Therapy Reviews Potassium Channel Blockers and Openers as CNS Neurologic Therapeutic Agents
Recent Patents on CNS Drug Discovery (Discontinued) Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Nutritional Attributes and Health Application of Seabuckthorn (<i>Hippophae rhamnoides</i> L.) – A Review
Current Nutrition & Food Science Control of Protein Synthesis in Malignant Transformation - the Role of eIF4E and the eIF4E Binding Proteins in the Regulation of Apoptosis
Current Cancer Therapy Reviews DNA Repair Inhibitors: The Next Major Step to Improve Cancer Therapy
Current Topics in Medicinal Chemistry Potential of Alphavirus Vectors in the Treatment of Advanced Solid Tumors
Recent Patents on Anti-Cancer Drug Discovery Novel PARP Inhibitor DDPF-20 Induces DNA Damage and Inhibits Angiogenesis through the PI3K/Akt/VEGF Pathway
Anti-Cancer Agents in Medicinal Chemistry Potential Clinical Applications of Multi-functional Milk Proteins and Peptides in Cancer Management
Current Medicinal Chemistry Characterization and Inhibition of the Recently Discovered Carbonic Anhydrase Isoforms CA XIII, XIV and XV
Current Topics in Medicinal Chemistry Distinct Epigenetic Reprogramming, Mitochondrial Patterns, Cellular Morphology, and Cytotoxicity after Bee Venom Treatment
Recent Patents on Anti-Cancer Drug Discovery β-estradiol Induces Mitochondrial Apoptosis in Cervical Cancer through the Suppression of AKT/NF-κB Signaling Pathway
Recent Patents on Anti-Cancer Drug Discovery Inhibitors of the Sphingosine Kinase Pathway as Potential Therapeutics
Current Cancer Drug Targets Botulinum Toxin a in Prostate Disease: A Venom from Bench to Bed-Side
Current Drug Delivery Transcription Factors as Targets for Cancer Therapy: AP-1 a Potential Therapeutic Target
Current Cancer Therapy Reviews CASC15: A Tumor-Associated Long Non-Coding RNA
Current Pharmaceutical Design Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Evaluation of Blood Pressure Control using a New Arterial Stiffness Parameter, Cardio-ankle Vascular Index (CAVI)
Current Hypertension Reviews